Christine Mikail Cvijic Sells 4,200 Shares of Neurogene (NASDAQ:NGNE) Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,200 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total value of $151,746.00. Following the completion of the transaction, the chief financial officer directly owned 84,040 shares of the company’s stock, valued at approximately $3,036,365.20. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Monday, July 6th, Christine Mikail Cvijic sold 600 shares of Neurogene stock. The shares were sold at an average price of $36.02, for a total transaction of $21,612.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total value of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The shares were sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The shares were sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Stock Up 3.9%

Shares of Neurogene stock opened at $38.24 on Thursday. The firm has a market cap of $604.19 million, a PE ratio of -8.40 and a beta of 1.68. Neurogene Inc. has a 52 week low of $15.93 and a 52 week high of $39.30. The business’s fifty day simple moving average is $29.92 and its 200-day simple moving average is $23.70.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09). As a group, equities analysts expect that Neurogene Inc. will post -5.63 earnings per share for the current year.

Institutional Trading of Neurogene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares during the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after purchasing an additional 1,008 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Neurogene by 12.8% during the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after purchasing an additional 2,950 shares in the last quarter. Finally, Daiwa Securities Group Inc. purchased a new stake in shares of Neurogene in the 4th quarter valued at about $66,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Analyst Upgrades and Downgrades

NGNE has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Rodman & Renshaw initiated coverage on shares of Neurogene in a research note on Wednesday, June 3rd. They set a “buy” rating and a $70.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Neurogene in a report on Tuesday, June 9th. UBS Group set a $70.00 price target on shares of Neurogene in a research note on Wednesday, June 3rd. Finally, Guggenheim initiated coverage on shares of Neurogene in a research report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $84.83.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.